News Agency
The Times

Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

  • Written by PR Newswire
  • IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile
  • IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD)
  • An interim data readout in AA is expected in Q3 2024

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Inmagene...

Read more: Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with...

Why Shopify Web Development Is Important For Modern Online Stores

A successful online store requires more than attractive product images and basic functionality. Businesses need websites that load quickly, provide smooth navigation, and create a reliable shopping experience across all devices. Professional Shopify web development helps businesses build scalable eCommerce stores... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion